Sukun Kim, Ph.D. - Related publications
Affiliations: | 2007 | University of California, Berkeley, Berkeley, CA |
Area:
Computer Architecture & Engineering (ARC); Energy (ENE); Operating Systems & Networking (OSNT); Programming Systems (PS); Security (SEC); Parallel architecture; High-performance networks; Workstation clusters
NOTE: We are testing a new system for identifying relevant work based on semantic analysis that identifies similarities between recently published papers and the current author's publications. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches.
50 most relevant papers in past 60 days:
50 most relevant papers in past 60 days:
| Year | Citation | Score | |
|---|---|---|---|
| 2021 | Choueiri TK, Atkins MB, Rose TL, Alter RS, Ju Y, Niland K, Wang Y, Arbeit R, Parasuraman S, Gan L, McDermott DF. A phase 1b trial of the CXCR4 inhibitor mavorixafor and nivolumab in advanced renal cell carcinoma patients with no prior response to nivolumab monotherapy. Investigational New Drugs. PMID 33507454 DOI: 10.1007/s10637-020-01058-2 | ||
| 2021 | Wang K, Wang H, Lv Y, Liu H, Liu J, Zhang Y. Camrelizumab combined with lenvatinib in the treatment of gastric cancer with liver metastasis: a case report. Annals of Palliative Medicine. 10: 803-809. PMID 33545802 DOI: 10.21037/apm-20-2572 | ||
| 2021 | Romani C, Salviato E, Paderno A, Zanotti L, Ravaggi A, Deganello A, Berretti G, Gualtieri T, Marchini S, D'Incalci M, Mattavelli D, Piazza C, Bossi P, Romualdi C, Nicolai P, et al. Genome-wide study of salivary miRNAs identifies miR-423-5p as promising diagnostic and prognostic biomarker in oral squamous cell carcinoma. Theranostics. 11: 2987-2999. PMID 33456584 DOI: 10.7150/thno.45157 | ||
| 2021 | How JA, Jazaeri A, Westin SN, Sood AK, Ramondetta LM, Xu M, Abonofal A, Karp DD, Subbiah V, Stephen B, Rodon JA, Yang F, Naing A. The clinical efficacy and safety of single-agent pembrolizumab in patients with recurrent granulosa cell tumors of the ovary: a case series from a phase II basket trial. Investigational New Drugs. PMID 33415580 DOI: 10.1007/s10637-020-01043-9 | ||
| 2021 | Okabe N, Mine H, Takagi H, Watanabe M, Muto S, Matsumura Y, Shio Y, Suzuki H. Pulmonary large cell carcinoma, highly positive for PD-L1, shows marked response to pembrolizumab: A case report. Thoracic Cancer. PMID 33605014 DOI: 10.1111/1759-7714.13850 | ||
| 2021 | Yue D, Qian J, Chen Z, Zhang B, Chen P, Zhang L, Li J, Zhang H, Wang C. Short-term response to immune-chemotherapy and immune features of a ceritinib-resistant patient with -rearranged lung adenocarcinoma. Journal For Immunotherapy of Cancer. 9. PMID 33558279 DOI: 10.1136/jitc-2020-001967 | ||
| 2021 | Tajima H, Makino I, Gabata R, Okazaki M, Ohbatake Y, Shimbashi H, Nakanuma S, Saitoh H, Shimada M, Yamaguchi T, Okamoto K, Moriyama H, Kinoshita J, Nakamura K, Miyashita T, et al. A phase I study of preoperative (neoadjuvant) chemotherapy with gemcitabine plus -paclitaxel for resectable pancreatic cancer. Molecular and Clinical Oncology. 14: 26. PMID 33414907 DOI: 10.3892/mco.2020.2188 | ||
| 2021 | Chu QS, Bouganim N, Fortier C, Zaknoen S, Stille JR, Kremer JD, Yuen E, Hui YH, de la Peña A, Lithio A, Smith PS, Batist G. Aurora kinase A inhibitor, LY3295668 erbumine: a phase 1 monotherapy safety study in patients with locally advanced or metastatic solid tumors. Investigational New Drugs. PMID 33479856 DOI: 10.1007/s10637-020-01049-3 | ||
| 2021 | Hasan MJ, Rabbani R, Anam AM, Huq SMR. Additional baricitinib loading dose improves clinical outcome in COVID-19. Open Medicine (Warsaw, Poland). 16: 41-46. PMID 33364433 DOI: 10.1515/med-2021-0010 | ||
| 2021 | Karlsson MJ, Costa Svedman F, Tebani A, Kotol D, Höiom V, Fagerberg L, Edfors F, Uhlén M, Egyhazi Brage S, Maddalo G. Inflammation and apolipoproteins are potential biomarkers for stratification of cutaneous melanoma patients for immunotherapy and targeted therapy. Cancer Research. PMID 33574091 DOI: 10.1158/0008-5472.CAN-20-2000 | ||
| 2021 | Montrone M, Longo V, Catino A, Pizzutilo P, Galetta D. [Efficacy of pralsetinib in a patient with advanced lung adenocarcinoma positive for RET rearrangement: the importance of Comprehensive Genomic Profiling.] Recenti Progressi in Medicina. 112: 10e-13e. PMID 33512367 DOI: 10.1701/3525.35132 | ||
| 2021 | Alkassis S, Alshare B, Ahmed S. Maintained Complete Response and Long-Term Survival in Epidermal Growth Factor Receptor Mutated Metastatic Non-Small Cell Lung Cancer with Erlotinib. Cureus. 13: e12451. PMID 33552769 DOI: 10.7759/cureus.12451 | ||
| 2021 | Naidus E, Bouquet J, Oh DY, Looney TJ, Yang H, Fong L, Standifer NE, Zhang L. Early changes in the circulating T cells are associated with clinical outcomes after PD-L1 blockade by durvalumab in advanced NSCLC patients. Cancer Immunology, Immunotherapy : Cii. PMID 33420629 DOI: 10.1007/s00262-020-02833-z | ||
| 2021 | Iwasaki H, Toda S, Murayama D, Kato S, Matsui A. Surgical indications and clinical management of benign and malignant follicular thyroid tumors: An algorithmic-based approach. Molecular and Clinical Oncology. 14: 32. PMID 33414913 DOI: 10.3892/mco.2020.2194 | ||
| 2021 | Chen S, Sun J, Zhao L, Sun Y, Jia D, Song Y, Luo J, Lei H, Liu N. Safety of apatinib plus S-1 for advanced solid tumor as palliative treatment. Experimental and Therapeutic Medicine. 21: 62. PMID 33365062 DOI: 10.3892/etm.2020.9494 | ||
| 2021 | Edwards BD, Edwards J, Cooper R, Kunimoto D, Somayaji R, Fisher D. Rifampin-resistant/multidrug-resistant Tuberculosis in Alberta, Canada: Epidemiology and treatment outcomes in a low-incidence setting. Plos One. 16: e0246993. PMID 33592031 DOI: 10.1371/journal.pone.0246993 | ||
| 2021 | Matsuda A, Yamada T, Matsumoto S, Shinji S, Ohta R, Sonoda H, Takahashi G, Iwai T, Takeda K, Sekiguchi K, Yoshida H. Systemic Chemotherapy is a Promising Treatment Option for Patients with Colonic Stents: A Review. Journal of the Anus, Rectum and Colon. 5: 1-10. PMID 33537495 DOI: 10.23922/jarc.2020-061 | ||
| 2021 | Avaliani T, Sereda Y, Davtyan H, Tukvadze N, Togonidze T, Kiria N, Denisiuk O, Gozalov O, Ahmedov S, Hovhannesyan A. Effectiveness and safety of fully oral modified shorter treatment regimen for multidrug-resistant tuberculosis in Georgia, 2019-2020. Monaldi Archives For Chest Disease = Archivio Monaldi Per Le Malattie Del Torace. 91. PMID 33470088 DOI: 10.4081/monaldi.2021.1679 | ||
| 2021 | Long ZY, Lu Y, Li M, Chen G, Shi L, Xiao X, Bai Y, Zhang HM, Wang Z. Effective treatment of anlotinib in giant delayed pulmonary metastasis of osteosarcoma: a case report and literature review. Annals of Palliative Medicine. PMID 33548989 DOI: 10.21037/apm-20-1790 | ||
| 2021 | Chen S, Lin W, Wen J, Xie B, Chen L, Chen G. Is glucagon-like peptide 1 receptor analogues effective and safe in severe COVID-19 patients with type 2 diabetes?-a case report. Annals of Palliative Medicine. PMID 33440950 DOI: 10.21037/apm-20-1982 | ||
| 2021 | Sapienza LG, Nasra K, Berry R, Danesh L, Little T, Abu-Isa E. Clinical effects of morning and afternoon radiotherapy on high-grade gliomas. Chronobiology International. 1-10. PMID 33557650 DOI: 10.1080/07420528.2021.1880426 | ||
| 2021 | Sarhan RM, Madney YM, Abou Warda AE, Boshra MS. Therapeutic efficacy, mechanical ventilation, length of hospital stay, and mortality rate in severe COVID-19 patients treated with tocilizumab. International Journal of Clinical Practice. e14079. PMID 33550688 DOI: 10.1111/ijcp.14079 | ||
| 2021 | Sheng J, Zhang J, Baudelet C, Roy A. Clinical Benefit-Risk Assessment of Nivolumab 240 mg Q2W in Chinese Patients With Advanced and Metastatic Solid Tumors. Journal of Clinical Pharmacology. PMID 33501654 DOI: 10.1002/jcph.1821 | ||
| 2021 | Nassif EF, Mlecnik B, Thibault C, Auvray M, Bruni D, Colau A, Compérat E, Bindea G, Catteau A, Fugon A, Boquet I, Martel M, Camparo P, Colin P, Zakopoulou R, et al. The Immunoscore in Localized Urothelial Carcinoma Treated with Neoadjuvant Chemotherapy: Clinical Significance for Pathologic Responses and Overall Survival. Cancers. 13. PMID 33525361 DOI: 10.3390/cancers13030494 | ||
| 2021 | Roboz GJ, Desai P, Lee S, Ritchie EK, Winer ES, DeMario M, Brennan B, Nüesch E, Chesne E, Brennan L, Lechner K, Kornacker M, DeAngelo DJ. A dose escalation study of RO6870810/TEN-10 in patients with acute myeloid leukemia and myelodysplastic syndrome. Leukemia & Lymphoma. 1-13. PMID 33586590 DOI: 10.1080/10428194.2021.1881509 | ||
| 2021 | Jacob A, Shook J, Hutson T. The implementation of lenvatinib/everolimus or lenvatinib/pembrolizumab combinations in the treatment of metastatic renal cell carcinoma. Expert Review of Anticancer Therapy. 1-8. PMID 33393393 DOI: 10.1080/14737140.2021.1868994 | ||
| 2021 | Body A, Prenen H, Lam M, Davies A, Tipping-Smith S, Lum C, Liow E, Segelov E. Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Recent Advances and Ongoing Challenges. Clinical Colorectal Cancer. PMID 33531256 DOI: 10.1016/j.clcc.2020.12.005 | ||
| 2021 | Isoda K, Nakade J, Suga Y, Fujita A, Shimada T, Sai Y. Initial Serum C-reactive Protein Level as a Predictor of Increasing Serum Vancomycin Concentration During Treatment. Therapeutic Drug Monitoring. PMID 33538550 DOI: 10.1097/FTD.0000000000000870 | ||
| 2021 | Fan L, Liu H, Li N, Liu C, Gu Y, Liu Y, Chen Y. Medical treatment of 55 patients with COVID-19 from seven cities in northeast China who fully recovered: A single-center, retrospective, observational study. Medicine. 100: e23923. PMID 33466134 DOI: 10.1097/MD.0000000000023923 | ||
| 2021 | Furihata K, Ishiguro Y, Yoshimura N, Ito H, Katsushima S, Kaneko E, Shimabe M, Mukai M, Watanabe R, Morishige T. A Phase 1 Study of KHK4083: A Single-Blind, Randomized, Placebo-Controlled Single-Ascending-Dose Study in Healthy Adults and an Open-Label Multiple-Dose Study in Patients With Ulcerative Colitis. Clinical Pharmacology in Drug Development. PMID 33512065 DOI: 10.1002/cpdd.918 | ||
| 2021 | Cruz LR, Baladrón I, Rittoles A, Díaz PA, Valenzuela C, Santana R, Vázquez MM, García A, Chacón D, Thompson D, Perera G, González A, Reyes R, Torres L, Pérez J, ... , et al. Treatment with an Anti-CK2 Synthetic Peptide Improves Clinical Response in COVID-19 Patients with Pneumonia. A Randomized and Controlled Clinical Trial. Acs Pharmacology & Translational Science. 4: 206-212. PMID 33615173 DOI: 10.1021/acsptsci.0c00175 | ||
| 2021 | Kemp Bohan PM, Chick RC, O'Shea AE, Vreeland TJ, Hickerson AT, Cindass JL, Ensley DC, Hale D, Clifton GT, Sohn VY, Thompson IM, Peoples GE, Liss MA. Phase I Trial of Encapsulated Rapamycin in Prostate Cancer Patients Under Active Surveillance to Prevent Progression. Cancer Prevention Research (Philadelphia, Pa.). PMID 33514567 DOI: 10.1158/1940-6207.CAPR-20-0383 | ||
| 2021 | Salgado Filho N, Lages JS, Brito DJA, Santos EJF, Dos Santos AM, de Souza FL, Mendes VGG, Silva GADS, Carneiro ECRL, Muniz MPR, Silva GEB, Sesso RCC. Variability in Hemoglobin Levels and the Factors Associated with Mortality in Hemodialysis Patients: A 78-Month Follow-Up Study. International Journal of Environmental Research and Public Health. 18. PMID 33530448 DOI: 10.3390/ijerph18031078 | ||
| 2021 | Yin MP, Xie PF, Zhao Y, He W, Ma YZ, Li CX, Li Z, Zeng YW, Wu G. Clinical Evaluation of Transarterial Infusion Chemotherapy for Advanced Esophageal Cancer. Journal of Cancer. 12: 1493-1498. PMID 33531994 DOI: 10.7150/jca.46877 | ||
| 2021 | Kato T, Matsuhashi N, Tomita H, Takahashi T, Iwata Y, Fukada M, Yasufuku I, Suetsugu T, Imai T, Mori R, Imai H, Tanaka Y, Okumura N, Hara A, Yoshida K. MYC Up-regulation Is a Useful Biomarker for Preoperative Neoadjuvant Chemotherapy Combined With Anti-EGFR in Liver Metastasis from Colorectal Cancer. In Vivo (Athens, Greece). 35: 203-213. PMID 33402467 DOI: 10.21873/invivo.12249 | ||
| 2021 | Cohen YC, Zada M, Wang SY, Bornstein C, David E, Moshe A, Li B, Shlomi-Loubaton S, Gatt ME, Gur C, Lavi N, Ganzel C, Luttwak E, Chubar E, Rouvio O, et al. Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing. Nature Medicine. PMID 33619369 DOI: 10.1038/s41591-021-01232-w | ||
| 2021 | Bhuiyan AS, Bari MA, Aditya G, Chowdhury UW, Wahab MA, Rahman MM, Islam MS, Rahman MM, Sharker MA, Rahman MS, Hossain M. Prevalence and Pattern of Dyslipidemia in Diabetes Mellitus Patients Admitted in the Department of Cardiology, Mymensingh Medical College Hospital, Mymensingh, Bangladesh. Mymensingh Medical Journal : Mmj. 30: 21-27. PMID 33397846 | ||
| 2021 | Zhang F, Gao F, Wang K, Liu X, Zhang Z. MiR-34a inhibitor protects mesenchymal stem cells from hyperglycaemic injury through the activation of the SIRT1/FoxO3a autophagy pathway. Stem Cell Research & Therapy. 12: 115. PMID 33546760 DOI: 10.1186/s13287-021-02183-2 | ||
| 2021 | Xu Z, Zhang Y, Yu YH. Successful treatment of advanced alveolar soft part sarcoma with camrelizumab combined with apatinib: a case report. Annals of Palliative Medicine. 10: 785-792. PMID 33545800 DOI: 10.21037/apm-20-2275 | ||
| 2021 | Sugawara R, Sugiyama H, Nakamura K, Tohgi K, Hongo T, Tsuchiya M, Momoki N, Nose S, Yutani C, Ikeda Y, Ikeda T, Ito H. Electron Microscopy Revealed Massive Lipid Droplets in Cardiomyocytes in a Patient with Cardiogenic Shock Following a Fulminant Type 1 Diabetes Mellitus. International Heart Journal. 62: 197-200. PMID 33518659 DOI: 10.1536/ihj.20-537 | ||
| 2021 | Lipovy B, Holoubek J, Hanslianova M, Cvanova M, Klein L, Grossova I, Zajicek R, Bukovcan P, Koller J, Baran M, Lengyel P, Eimer L, Jandova M, Kostal M, Brychta P, et al. Impact of Antibiotics Associated with the Development of Toxic Epidermal Necrolysis on Early and Late-Onset Infectious Complications. Microorganisms. 9. PMID 33477980 DOI: 10.3390/microorganisms9010202 | ||
| 2021 | Giavedoni P, Martinez C, Podlipnik S, Suárez-Lleidó M, Martí-Martí I, Morgado-Carrasco D, Rovira M, Fernández-Avilés F, Gutiérrez G, Rosiñol L, Cid J, Lozano M, Mascaró JM. Assessment of Sclerodermoid Chronic Graft-versus-host Disease with Colour Doppler Ultrasound. Acta Dermato-Venereologica. PMID 33475145 DOI: 10.2340/00015555-3747 | ||
| 2021 | Santos M, Monteiro E. Time between Diagnosis and Treatment of Hypopharynx and Larynx Cancer: Are Longer Delays Associated with Higher Discrepancy between Clinical and Pathological Staging? International Archives of Otorhinolaryngology. 25: e108-e114. PMID 33542760 DOI: 10.1055/s-0040-1708898 | ||
| 2021 | Wang H, Hu L, Bai GQ, Liu Z, Yu GG, Wang W, Sun L. [Serum C-reactive protein, cholinesterase and prealbumin are correlated with prognosis of severe coronavirus disease 2019 patients]. Zhonghua Nei Ke Za Zhi. 60: 134-138. PMID 33503724 DOI: 10.3760/cma.j.cn112138-20200421-00404 | ||
| 2021 | Deng J, Chen W, Wu X, Zhou Y, Li J. Evaluating the predictive power of circulating tumor cells for the prognosis of transarterial chemoembolization treatment on patients with advanced hepatocellular carcinoma. Medicine. 100: e24060. PMID 33429769 DOI: 10.1097/MD.0000000000024060 | ||
| 2021 | van Ewijk R, Vaarwerk B, Breunis WB, Schoot RA, Ter Horst SAJ, van Rijn RR, van der Lee JH, Merks JHM. The Value of Early Tumor Size Response to Chemotherapy in Pediatric Rhabdomyosarcoma. Cancers. 13. PMID 33561094 DOI: 10.3390/cancers13030510 | ||
| 2021 | Akizawa T, Nobori K, Matsuda Y, Hayashi Y, Hayasaki T, Yamamoto H. Molidustat for anemia correction in Japanese patients undergoing hemodialysis: a single-arm, phase 3 study. Therapeutic Apheresis and Dialysis : Official Peer-Reviewed Journal of the International Society For Apheresis, the Japanese Society For Apheresis, the Japanese Society For Dialysis Therapy. PMID 33506635 DOI: 10.1111/1744-9987.13627 | ||
| 2021 | Yu Y, Wang Y, Wu L, Xu X, Zhou H, Wang Q, Zhou J. Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) combined with bevacizumab for advanced non-squamous non-small-cell lung cancer patients with gradual progression on EGFR-TKI treatment: A cohort study. Medicine. 100: e23712. PMID 33592829 DOI: 10.1097/MD.0000000000023712 | ||
| 2021 | An YW, Song S, Li WX, Chen YX, Hu XP, Zhao J, Li ZW, Jiang GY, Wang C, Wang JC, Yuan B, Liu HQ. Liver function recovery of COVID-19 patients after discharge, a follow-up study. International Journal of Medical Sciences. 18: 176-186. PMID 33390786 DOI: 10.7150/ijms.50691 | ||
| 2021 | Balzarotti M, Magagnoli M, Canales MÁ, Corradini P, Grande C, Sancho JM, Zaja F, Quinson AM, Belsack V, Maier D, Carlo-Stella C. A phase Ib, open-label, dose-escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory diffuse large B-cell lymphoma. Investigational New Drugs. PMID 33523334 DOI: 10.1007/s10637-020-01054-6 |